Evaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients

SM Hosseini^¹, H Shahbaziyan¹, S Razmjoo¹, N Jasemizade²

¹Department of radiation and oncology of Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran  ²MD student, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran  

DOI : http://dx.doi.org/10.13005/bbra/1894

ABSTRACT: Breast cancer is the most frequently diagnosed life-threatening cancer among women worldwide. Ki67 as a nuclear proliferation marker is used as a predictive marker for response to chemotherapy. In this study we retrospectively evaluated the association between Ki67 and 5 years disease free survival (5yDFS) in breast cancer patients. In addition, the correlation between ER, PR, HER2, and P53 and 5yDFS was studied. Total of 365 patients with breast cancer previously treated with surgery and/or chemoradiotherapy during 2001 to 2008 in department of were included in the study. All patients had invasive ductal carcinoma in the pathology. Age, Ki67, ER, PR, HER2, and P53 were studied. Her2/Neu expression level was assessed by reaction with antibodies against HER2/neu. Proliferation level was determined by reaction with antibodies against Ki-67: the level ≥14% considered high and the level <14% considered low. The frequency and percentage were used for qualification data and mean and Standard Deviation (SD) for the quantitative data. The mean level of ki67 was 16.85±16.63 and the frequency of high ki67 was 203 (55.6%). The mean age of breast cancer patients was 47.2±10.53. ER status was positive in 242 patients (66.3%). One hundred and fifty four breast cancer patients had PR negative (42.2%). The HER2 overexpression was identified in 96 tumors (26.3%). The P53 status in tumors was positive in 166 (45.5%). The 55.6% of the patients had 5yDFS. The 67.5% and 40.7% of breast cancer patients respectively with low level of Ki67 and high level of Ki67 showed significant correlation with 5yDFS. Our findings showed increased level of 5yDFS in ER positive breast cancer patients. In addition, the chance of high Ki67 is increased in the ER negative, HER2 negative, and P53 positive breast cancer patients.

KEYWORDS: Breast Cancer; molecular marker; Estrogen Receptor; Progesterone Receptor; HER2; Ki67; 5yDFS; P53  

[ HTML Full Text]